Amgen Inc (AMG) Stock Price & News

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia

About Amgen Inc

CEORobert A. Bradway

Employees31,5 миң

Founded1980-ж., 8-апр.

HeadquartersТаусанд Окс, Калифорния, Америка Кошмо Штаттары

Sector-

Websiteamgen.com

All values in USD	2025-ж. июн.	2025-ж. сен.	2025-ж. дек.	2026-ж. мар.
Revenue	9,18 млд	9,56 млд	9,87 млд	8,62 млд
Cost of goods sold	2,67 млд	2,74 млд	2,68 млд	2,50 млд
Cost of revenue	2,67 млд	2,74 млд	2,68 млд	2,50 млд
Research and development expenses	1,74 млд	1,90 млд	2,14 млд	1,72 млд
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,69 млд	1,72 млд	1,95 млд	1,60 млд
Operating expense	3,50 млд	3,55 млд	4,18 млд	3,21 млд
Total operating expenses	6,18 млд	6,29 млд	6,85 млд	5,70 млд
Operating income	3,00 млд	3,26 млд	3,01 млд	2,91 млд
Other non operating income	-113,00 млн	181,00 млн	143,00 млн	192,00 млн
EBT including unusual items	1,57 млд	3,92 млд	1,51 млд	2,08 млд
EBT excluding unusual items	2,37 млд	2,72 млд	2,51 млд	2,37 млд
Income tax expense	136,00 млн	705,00 млн	181,00 млн	265,00 млн
Effective tax rate	8,67%	17,98%	11,96%	12,72%
Other operating expenses	68,00 млн	-71,00 млн	82,00 млн	-113,00 млн
Net income	1,43 млд	3,22 млд	1,33 млд	1,82 млд
Net profit margin	15,60%	33,65%	13,51%	21,11%
Earnings per share	6,02	5,64	5,29	5,15
Interest and investment income	-	-	408,00 млн	-
Interest expense	-694,00 млн	-685,00 млн	-1,06 млд	-657,00 млн
Net interest expenses	-694,00 млн	-685,00 млн	-653,00 млн	-657,00 млн
Depreciation and amortization charges	-	-	-	-
EBITDA	4,34 млд	4,57 млд	4,02 млд	4,03 млд
Gain or loss from assets sale	-	-	-	-

AI content may include mistakes. Learn more

HelpSend feedbackPrivacy Terms Disclaimer

Finance

Research